cas 3382-18-1|| where to buy 6,7-Dimethoxy-3,4-dihydroisoquinoline

Produktname:6,7-Dimethoxy-3,4-dihydroisoquinoline

IUPAC Name:6,7-dimethoxy-3,4-dihydroisoquinoline

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM119915-5g	in stock	ǕƄ
CM119915-25g	in stock	ƞźƄ
CM119915-100g	in stock	ǕƻȀ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 3382-18-1 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:3382-18-1; Molekulare Formel:C11H13NO2; Schmelzpunkt:-; SMILES-Code:COC1=CC2=C(C=C1OC)CCN=C2; Dichte:

: Katalognummer:CM119915; Molekulargewicht:191.23; Siedepunkt:322.8°C at 760 mmHg; Mdl-Nr.:MFCD00266748; Lagerung:Store at 2-8°C.

: Quinolines; Quinolines are an important class of biologically active heterocyclic compounds, and their derivatives usually exhibit a variety of biological activities. They can be used as antimalarial drugs and in the preparation of other antimalarial drugs. Other important activities of quinoline derivatives include inhibitory activity against EGFR-TK and antipsychotic activity. Futhermore, quinoline scaffolds are present in various drug molecules, including the antimalarial drugs aablaquine, chloroquine, mefloquine and primaquine, and the antibacterial agents gatifloxacin, levofloxacin, and moxifloxacin.; Quinoline Price; if you have any question on quinoline price, we will give the professional answers to your short questions.

: Valbenazine; Neurocrine Biosciences announced interim results from the ongoing open-label KINECT®-HD2 study about INGREZZA® (Valbenazine) capsules when used for the long-term treatment of adults with chorea associated with Huntington's disease (HD). Interim data suggest one-capsule, once-daily INGREZZA improved chorea at the first evaluation at Week 2 with sustained efficacy through Week 50. INGREZZA® (Valbenazine) is the only one-capsule, once-daily selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by FDA for the treatment of adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease (HD).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.